Developer docs
API playgroundTry for free, no card

Search company profiles

4D Path

Full company profile

uuid0000hfw

Namestring
4D Path
Legal namestring
4D Path Inc.
Websiteurl
4dpath.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewton, United States
HQ citystring
Newton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational pathology software, predictive oncology biomarkers, digital pathology AI platform, treatment response prediction, companion diagnostics development
Industry4 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Software Publishers5132
SIC code2 codes
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
Computational Pathology & Predictive Oncology Software
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Biopharma biomarker discovery and development partnerships
TypeProfessional Services
Description

Strategic collaborations with biopharmaceutical companies (e.g., Daiichi Sankyo for ADC program) to develop predictive biomarkers for specific therapeutic candidates — custom treatment prediction signatures developed per therapy of interest.

4dpath.com
2Clinical trial biomarker analytics
TypeManaged Services
Description

Exploratory biomarker collaboration in prospective clinical trials (e.g., Phase II DAD-IO trial supported by Gilead) where QPOR analyzes pre-treatment biopsy slides to generate predictive biomarkers — revenue tied to clinical trial engagements.

4dpath.com
3Strategic financing rounds (capital raises)
TypeSubscription Recurring
Description

Recurring private financing from strategic investors (e.g., 2026 first close of strategic financing; 2023 Form D exempt offering of approximately $16.97M; prior rounds totaling $6.4M as of December 2019) to fund platform development and clinical validation.

4dpath.com
4Platform distribution via PathPresenter ClinPx
TypeLicensing Royalties
Description

4D Q-plasia OncoReader Breast distributed through PathPresenter's Clinical Workflow Platform ClinPx (currently for Research Use Only) — generates reach through 40,000+ global pathologist users.

4dpath.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Pricing details1 tier
1Quote-based / partnership engagement for biopharma and clinical trial customers; QPOR Breast distributed via PathPresenter ClinPx (RUO).
ModelOtherBilling cadenceMulti-year contract
Notes

No public price list; product is for Research Use Only; partnerships with biopharma (e.g., Daiichi Sankyo) are custom negotiated.

4dpath.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1QPOR (Q-Plasia OncoReader)
Description

Cloud-based, AI-driven, deterministic software platform that converts digitized H&E biopsy images into quantitative, physics-informed treatment predictive biomarkers measuring cell cycle deregulations and tumor immune microenvironment dynamics.

4dpath.com
+1 more record
Core offering1 text field

4D Path develops and sells the Q-Plasia OncoReader (QPOR™) platform, a patented cloud-based AI software that converts digitized H&E-stained whole-slide biopsy and cytology images into predictive biomarkers of cancer therapy response by quantifying cell cycle deregulation and tumor immune microenvironment dynamics. The company sells its breast-cancer-specific 4D QPOR Breast product (FDA Breakthrough Device Designation) and develops customized treatment prediction signatures in partnership with biopharmaceutical companies, clinical research organizations, and academic cancer centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • >80% accuracy using QPOR vs ~40% standard of care in TNBC neoadjuvant chemotherapy response prediction (N=88); up to 98% with customized screen, >100% increase in %Responder
+5 more records
Product overview1 text field

4D Path offers a single unified, cloud-based AI platform — the patented Q-Plasia OncoReader (QPOR™) — under which it sells a beachhead product (4D QPOR Breast) and a growing portfolio of pan-cancer predictive biomarker signatures. The core QPOR™ engine ingests digitized H&E-stained biopsy and cytology whole-slide images, computes 29+ continuous-scale biological indices capturing cell-cycle deregulation and tumor immune-microenvironment dynamics, and outputs structured predictive biomarker reports. Layered on top of this core platform are productized offerings: 4D QPOR Breast (breast cancer, FDA Breakthrough Device Designation); the customized Treatment Prediction Signature (e.g., CmbINAC for germline BRCA HER2-negative breast cancer developed with TBCRC/DFCI); and a multi-indication portfolio of digital treatment-predictive biomarkers under development or in clinical trials for triple-negative breast cancer, bladder cancer, ovarian, lung, colorectal, melanoma, and additional ADC and immunotherapy programs.

Product and service3 records
1Q-Plasia OncoReader (QPOR™) Platform
CategoryComputational Pathology Software Platform
Description

Patented, cloud-based, fully automated AI software platform that converts digitized H&E whole-slide biopsy/resection and cytology images into biological signatures and predictive biomarkers by quantifying cell-cycle deregulation and tumor immune-microenvironment dynamics via statistical-physics-based analysis. Operates as an end-to-end image-to-report solution deployed on cloud infrastructure and integrated into existing PACS and digital pathology workflows. Sold to biopharmaceutical companies and clinical research organizations for biomarker co-development and clinical trial analytics.

24D Q-Plasia OncoReader Breast (4D QPOR Breast)
CategoryBreast Cancer Adjunct Diagnostic Software
Description

Beachhead product of the QPOR platform focused on breast cancer. Provides an adjunct diagnostic tool for histopathologists to improve diagnostic accuracy of breast cancer features (invasiveness, grade, HER2 status, hormone receptor status, Ki67) solely from H&E biopsy/resection images. Currently distributed for Research Use Only via PathPresenter's ClinPx Clinical Workflow Platform.

3Customized Treatment Prediction Signature (e.g., CmbINAC)
CategoryCustom Predictive Biomarker Service
Description

Custom-built predictive biomarker signature combining QPOR indices (e.g., IHI, PI, G1SI) to predict response to a specific therapy in a specific indication. Developed in collaboration with partners such as TBCRC and Dana-Farber Cancer Institute for biopharmaceutical clinical programs (e.g., ADC and neoadjuvant chemotherapy response).

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-21
Description

Partnership to bring QPOR platform to pharmaceutical companies and CROs working with VCTS. VCTS clients immediately gain access to physics-inspired, AI-driven deterministic platform that transforms routine biopsy images into clear treatment predictive biomarkers. Strengthens VCTS's position as a leader in oncology clinical trials.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-14
Description

Collaboration to develop next-generation predictive biomarkers for an antibody drug conjugate (ADC) clinical development program. 4D Path will apply QPOR to standard H&E-stained tumor biopsy slides to compute interpretable, quantitative biomarkers associated with cell-cycle deregulation and tumor microenvironment dynamics to identify patients most likely to benefit from the select ADC. Approach compatible with both retrospective analyses of archived clinical specimens and prospective evaluation in ongoing and future studies.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

4D Path joined as exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences. 4D Path will apply its QPOR platform to analyze pre-treatment biopsy slides and generate predictive biomarkers for response to a novel combination therapy of Sacituzumab Govitecan + Enfortumab Vedotin +/- Pembrolizumab in patients with locally advanced/metastatic urothelial carcinoma.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

Gilead Sciences supports the Phase II DAD-IO clinical trial in urothelial carcinoma (with Sacituzumab Govitecan, an ADC from Gilead). 4D Path serves as exploratory biomarker collaborator using QPOR to generate predictive biomarkers from pre-treatment biopsies.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-10
Description

Collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. QPOR platform runs natively on AMD EPYC CPUs on Oracle Cloud Infrastructure (OCI) to convert routine biopsy images into interpretable biomarkers of tumor and immune response. Achieves reproducibility, cost efficiency, scalability and regulatory-friendly insights for clinical trial execution.

6Translational Breast Cancer Research Consortium (TBCRC)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Long-standing research collaboration with TBCRC and Dana-Farber Cancer Institute (DFCI) on Phase II breast cancer trials (TBCRC 030, TBCRC 031). QPOR has predicted neoadjuvant chemotherapy response in TNBC and HER2-/ER+ breast cancer with >80% accuracy vs ~40% standard of care; 9X increased response odds in paclitaxel arm (TBCRC 030 published in JNCI).

4dpath.com
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2023-12-14
Description

Co-founder Dasgupta and Mukhopadhyay participated in a Friends of Cancer Research panel discussion on computational pathology in oncology drug development, contributing to a white paper on platform risk classification, transparency, and common reference standards.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-08
Description

Formal membership of Leeds Teaching Hospitals NHS Trust's Innovation Pop-Up, an international community of high-tech start-ups led by clinicians, scientists and entrepreneurs providing a test bed for new innovations before NHS implementation. Working with NHS Histopathology, University of Leeds, and University of Bradford to validate QPOR platform.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-08
Description

Collaboration to present new study at the 2023 National Society for Histotechnology (NSH) Convention on automated robust image analysis qualifying H&E staining adequacy with varying hematoxylin and eosin incubation times. Aligns 4D Path's image analysis with microscopy/imaging and histopathology product leaders.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-03-15
Description

Global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter's ClinPx Clinical Workflow Platform. Pathologists can run 4D Q-Plasia OncoReader Breast directly within the ClinPx whole slide image viewer (scanner-agnostic). Product is for Research Use Only (RUO); not FDA or EMA approved for primary diagnosis.

114D Path Scientific Advisory Board (Dr. Craig Bunnell, Dr. Stuart Schnitt, Dr. Eric Winer, Dr. Puay Hoon Tan, Dr. Lee Schwartzberg)
Strategic tierCoreTypeOthersAnnounced on2022-02-15
Description

Strategic advisory group of internationally recognized oncology, pathology and translational research leaders from Dana-Farber, Yale Cancer Center, Renown Health/OneOncology, Luma Medical Centre Singapore (WHO Classification Board member) — provides clinical direction, validates scientific foundation, and supports pan-cancer expansion.

4dpath.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-16
Description

Extended existing partnership through 2027 for collaborative validation of new technology to help doctors more accurately diagnose breast cancer. Successfully completed three breast cancer clinical studies at Leeds analyzing cases from over 1,000 patients across multiple trials; plans to expand trials to skin, lung, gynecological and head and neck cancers.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Paige builds AI-enabled digital pathology products for cancer diagnosis and has secured multiple FDA clearances (including the first FDA-authorized AI pathology product). It is the closest direct competitor to 4D Path in applying AI to H&E whole-slide images for oncology decision support.

TypeDirect peer
Description

PathAI provides AI-powered pathology platforms used by biopharma sponsors for biomarker discovery and by health systems for diagnostic decision support. Like 4D Path, it offers both companion-diagnostic-style biopharma analytics and clinical pathology AI, making it a directly comparable peer.

TypeDirect peer
Description

Ibex develops AI-based cancer diagnostics for pathology, with deployments in clinical labs across multiple geographies for breast, prostate, and GI cancers. It is a direct peer in AI-driven H&E interpretation for oncology and competes for the same clinical and biopharma customers.

TypeDirect peer
Description

Owkin applies AI to pathology and multimodal patient data to discover biomarkers and predict treatment response for biopharma R&D. Its federated-learning approach to digital pathology and biopharma partnership model closely mirrors 4D Path's positioning with pharma sponsors.

TypeDirect peer
Description

Proscia offers a digital pathology platform with built-in AI applications for routine pathology workflows and biomarker quantification. It targets biopharma and clinical labs with H&E-centric AI tools, overlapping materially with QPOR's beachhead product positioning.

TypeBroad incumbent
Description

SOPHiA GENETICS operates a broader AI-driven genomic and multimodal analytics platform used by hospitals and pharma, including Erin Feeney (4D Path's CCO) previously. It is comparable as a broader AI-diagnostics incumbent with oncology applications, though its core modality is genomics rather than H&E image-based biomarkers.

7Tempus Labs
TypeBroad incumbent
Description

Tempus is a large, well-capitalized precision medicine company combining molecular and imaging data (including pathology AI) with clinical data to serve biopharma and providers. It competes for the same biopharma biomarker budgets but across a much broader multi-omics portfolio.

TypeBroad incumbent
Description

Roche's Ventana digital pathology business provides slide scanners, image management, and AI-augmented algorithms integrated into a global pathology ecosystem. It is an incumbent serving similar pathologist end users and biopharma partners, with portfolio scale that exceeds 4D Path's offering.

TypeBroad incumbent
Description

Philips offers the IntelliSite Digital Pathology platform (iSyntax format, supported by QPOR) along with AI-driven pathology applications. It is comparable as a broad incumbent scanner and workflow vendor reaching the same pathologist and clinical-trial customer base.

TypeEmerging player
Description

Strata Oncology focuses on molecular profiling and precision oncology decision support, including treatment selection for advanced cancer patients. It overlaps with 4D Path on the precision oncology / companion-diagnostic axis but primarily uses molecular rather than H&E image-based biomarkers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

4D Path

Computational Pathology & Predictive Oncology Software4dpath.com

4D Path firmographics

Firmographics
Name
4D Path
Legal name
4D Path Inc.
Website
https://4dpath.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

4D Path industry classification

Industry
Product category
Computational Pathology & Predictive Oncology Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Software Publishers (5132)
SIC
Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)

Keywords

  • Computational pathology software
  • Predictive oncology biomarkers
  • Digital pathology AI platform
  • Treatment response prediction
  • Companion diagnostics development

Where 4D Path is headquartered

Location

Headquarters

HQ city
Newton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

4D Path business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Biopharma biomarker discovery and development partnerships: Strategic collaborations with biopharmaceutical companies (e.g., Daiichi Sankyo for ADC program) to develop predictive biomarkers for specific therapeutic candidates — custom treatment prediction signatures developed per therapy of interest.
  2. Clinical trial biomarker analytics: Exploratory biomarker collaboration in prospective clinical trials (e.g., Phase II DAD-IO trial supported by Gilead) where QPOR analyzes pre-treatment biopsy slides to generate predictive biomarkers — revenue tied to clinical trial engagements.
  3. Strategic financing rounds (capital raises): Recurring private financing from strategic investors (e.g., 2026 first close of strategic financing; 2023 Form D exempt offering of approximately $16.97M; prior rounds totaling $6.4M as of December 2019) to fund platform development and clinical validation.
  4. Platform distribution via PathPresenter ClinPx: 4D Q-plasia OncoReader Breast distributed through PathPresenter's Clinical Workflow Platform ClinPx (currently for Research Use Only) — generates reach through 40,000+ global pathologist users.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based / partnership engagement for biopharma and clinical trial customers; QPOR Breast distributed via PathPresenter ClinPx (RUO).

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

4D Path product offering

Product offering

Core offering

4D Path develops and sells the Q-Plasia OncoReader (QPOR™) platform, a patented cloud-based AI software that converts digitized H&E-stained whole-slide biopsy and cytology images into predictive biomarkers of cancer therapy response by quantifying cell cycle deregulation and tumor immune microenvironment dynamics. The company sells its breast-cancer-specific 4D QPOR Breast product (FDA Breakthrough Device Designation) and develops customized treatment prediction signatures in partnership with biopharmaceutical companies, clinical research organizations, and academic cancer centers.

Product overview

4D Path offers a single unified, cloud-based AI platform — the patented Q-Plasia OncoReader (QPOR™) — under which it sells a beachhead product (4D QPOR Breast) and a growing portfolio of pan-cancer predictive biomarker signatures. The core QPOR™ engine ingests digitized H&E-stained biopsy and cytology whole-slide images, computes 29+ continuous-scale biological indices capturing cell-cycle deregulation and tumor immune-microenvironment dynamics, and outputs structured predictive biomarker reports. Layered on top of this core platform are productized offerings: 4D QPOR Breast (breast cancer, FDA Breakthrough Device Designation); the customized Treatment Prediction Signature (e.g., CmbINAC for germline BRCA HER2-negative breast cancer developed with TBCRC/DFCI); and a multi-indication portfolio of digital treatment-predictive biomarkers under development or in clinical trials for triple-negative breast cancer, bladder cancer, ovarian, lung, colorectal, melanoma, and additional ADC and immunotherapy programs.

Differentiator

Problem solved

Functional benefit

Brands

  • QPOR (Q-Plasia OncoReader): Cloud-based, AI-driven, deterministic software platform that converts digitized H&E biopsy images into quantitative, physics-informed treatment predictive biomarkers measuring cell cycle deregulations and tumor immune microenvironment dynamics.
  • 4D Q-Plasia OncoReader Breast (QPOR Breast)

Products and services

  • Q-Plasia OncoReader (QPOR™) Platform Patented, cloud-based, fully automated AI software platform that converts digitized H&E whole-slide biopsy/resection and cytology images into biological signatures and predictive biomarkers by quantifying cell-cycle deregulation and tumor immune-microenvironment dynamics via statistical-physics-based analysis. Operates as an end-to-end image-to-report solution deployed on cloud infrastructure and integrated into existing PACS and digital pathology workflows. Sold to biopharmaceutical companies and clinical research organizations for biomarker co-development and clinical trial analytics.
  • 4D Q-Plasia OncoReader Breast (4D QPOR Breast) Beachhead product of the QPOR platform focused on breast cancer. Provides an adjunct diagnostic tool for histopathologists to improve diagnostic accuracy of breast cancer features (invasiveness, grade, HER2 status, hormone receptor status, Ki67) solely from H&E biopsy/resection images. Currently distributed for Research Use Only via PathPresenter's ClinPx Clinical Workflow Platform.
  • Customized Treatment Prediction Signature (e.g., CmbINAC) Custom-built predictive biomarker signature combining QPOR indices (e.g., IHI, PI, G1SI) to predict response to a specific therapy in a specific indication. Developed in collaboration with partners such as TBCRC and Dana-Farber Cancer Institute for biopharmaceutical clinical programs (e.g., ADC and neoadjuvant chemotherapy response).

Quantifiable outcome

  • >80% accuracy using QPOR vs ~40% standard of care in TNBC neoadjuvant chemotherapy response prediction (N=88); up to 98% with customized screen, >100% increase in %Responder
  • +5 more outcomes

Companies that use 4D Path

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

4D Path technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature8 records

4D Path partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, flagship and minor.

  • Versiti Clinical Trials Services (VCTS)coreChannel Partner/ Reseller/ Distributor · 21 April 2026Partnership to bring QPOR platform to pharmaceutical companies and CROs working with VCTS. VCTS clients immediately gain access to physics-inspired, AI-driven deterministic platform that transforms routine biopsy images into clear treatment predictive biomarkers. Strengthens VCTS's position as a leader in oncology clinical trials.
  • Daiichi SankyoflagshipStrategic or Co-development Partner · 14 April 2026Collaboration to develop next-generation predictive biomarkers for an antibody drug conjugate (ADC) clinical development program. 4D Path will apply QPOR to standard H&E-stained tumor biopsy slides to compute interpretable, quantitative biomarkers associated with cell-cycle deregulation and tumor microenvironment dynamics to identify patients most likely to benefit from the select ADC. Approach compatible with both retrospective analyses of archived clinical specimens and prospective evaluation in ongoing and future studies.
  • Dana-Farber Cancer InstituteflagshipStrategic or Co-development Partner · 22 January 20264D Path joined as exploratory biomarker collaborator in the Phase II DAD-IO clinical study (NCT04724018) led by Dana-Farber Cancer Institute and supported by Gilead Sciences. 4D Path will apply its QPOR platform to analyze pre-treatment biopsy slides and generate predictive biomarkers for response to a novel combination therapy of Sacituzumab Govitecan + Enfortumab Vedotin +/- Pembrolizumab in patients with locally advanced/metastatic urothelial carcinoma.
  • Gilead SciencesflagshipStrategic or Co-development Partner · 22 January 2026Gilead Sciences supports the Phase II DAD-IO clinical trial in urothelial carcinoma (with Sacituzumab Govitecan, an ADC from Gilead). 4D Path serves as exploratory biomarker collaborator using QPOR to generate predictive biomarkers from pre-treatment biopsies.
  • AMD and Oracle (Oracle Cloud Infrastructure)coreTechnology or Integration · 10 December 2025Collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. QPOR platform runs natively on AMD EPYC CPUs on Oracle Cloud Infrastructure (OCI) to convert routine biopsy images into interpretable biomarkers of tumor and immune response. Achieves reproducibility, cost efficiency, scalability and regulatory-friendly insights for clinical trial execution.
  • Translational Breast Cancer Research Consortium (TBCRC)flagshipStrategic or Co-development Partner · 1 January 2024Long-standing research collaboration with TBCRC and Dana-Farber Cancer Institute (DFCI) on Phase II breast cancer trials (TBCRC 030, TBCRC 031). QPOR has predicted neoadjuvant chemotherapy response in TNBC and HER2-/ER+ breast cancer with >80% accuracy vs ~40% standard of care; 9X increased response odds in paclitaxel arm (TBCRC 030 published in JNCI).
  • Friends of Cancer ResearchminorGTM or Marketing Partner · 14 December 2023Co-founder Dasgupta and Mukhopadhyay participated in a Friends of Cancer Research panel discussion on computational pathology in oncology drug development, contributing to a white paper on platform risk classification, transparency, and common reference standards.
  • Leeds Teaching Hospitals NHS Trust (Innovation Pop-Up)coreStrategic or Co-development Partner · 8 November 2023Formal membership of Leeds Teaching Hospitals NHS Trust's Innovation Pop-Up, an international community of high-tech start-ups led by clinicians, scientists and entrepreneurs providing a test bed for new innovations before NHS implementation. Working with NHS Histopathology, University of Leeds, and University of Bradford to validate QPOR platform.
  • Evident Scientific and Sakura Finetek USAminorStrategic or Co-development Partner · 8 September 2023Collaboration to present new study at the 2023 National Society for Histotechnology (NSH) Convention on automated robust image analysis qualifying H&E staining adequacy with varying hematoxylin and eosin incubation times. Aligns 4D Path's image analysis with microscopy/imaging and histopathology product leaders.
  • PathPresentercoreOEM/ Whitelabel/ Licensing Partner · 15 March 2022Global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter's ClinPx Clinical Workflow Platform. Pathologists can run 4D Q-Plasia OncoReader Breast directly within the ClinPx whole slide image viewer (scanner-agnostic). Product is for Research Use Only (RUO); not FDA or EMA approved for primary diagnosis.
  • 4D Path Scientific Advisory Board (Dr. Craig Bunnell, Dr. Stuart Schnitt, Dr. Eric Winer, Dr. Puay Hoon Tan, Dr. Lee Schwartzberg)coreOthers · 15 February 2022Strategic advisory group of internationally recognized oncology, pathology and translational research leaders from Dana-Farber, Yale Cancer Center, Renown Health/OneOncology, Luma Medical Centre Singapore (WHO Classification Board member) — provides clinical direction, validates scientific foundation, and supports pan-cancer expansion.
  • University of LeedscoreStrategic or Co-development Partner · 16 March 2021Extended existing partnership through 2027 for collaborative validation of new technology to help doctors more accurately diagnose breast cancer. Successfully completed three breast cancer clinical studies at Leeds analyzing cases from over 1,000 patients across multiple trials; plans to expand trials to skin, lung, gynecological and head and neck cancers.

Scale indicators14 records

Recent moves6 records

Expansion highlights7 records

4D Path competitors and assessment

Company assessment

Direct peers

  • Paige.AI: Paige builds AI-enabled digital pathology products for cancer diagnosis and has secured multiple FDA clearances (including the first FDA-authorized AI pathology product). It is the closest direct competitor to 4D Path in applying AI to H&E whole-slide images for oncology decision support.
  • PathAI: PathAI provides AI-powered pathology platforms used by biopharma sponsors for biomarker discovery and by health systems for diagnostic decision support. Like 4D Path, it offers both companion-diagnostic-style biopharma analytics and clinical pathology AI, making it a directly comparable peer.
  • Ibex Medical Analytics: Ibex develops AI-based cancer diagnostics for pathology, with deployments in clinical labs across multiple geographies for breast, prostate, and GI cancers. It is a direct peer in AI-driven H&E interpretation for oncology and competes for the same clinical and biopharma customers.
  • Owkin: Owkin applies AI to pathology and multimodal patient data to discover biomarkers and predict treatment response for biopharma R&D. Its federated-learning approach to digital pathology and biopharma partnership model closely mirrors 4D Path's positioning with pharma sponsors.
  • Proscia: Proscia offers a digital pathology platform with built-in AI applications for routine pathology workflows and biomarker quantification. It targets biopharma and clinical labs with H&E-centric AI tools, overlapping materially with QPOR's beachhead product positioning.

Broad incumbents

  • SOPHiA GENETICS: SOPHiA GENETICS operates a broader AI-driven genomic and multimodal analytics platform used by hospitals and pharma, including Erin Feeney (4D Path's CCO) previously. It is comparable as a broader AI-diagnostics incumbent with oncology applications, though its core modality is genomics rather than H&E image-based biomarkers.
  • Tempus Labs: Tempus is a large, well-capitalized precision medicine company combining molecular and imaging data (including pathology AI) with clinical data to serve biopharma and providers. It competes for the same biopharma biomarker budgets but across a much broader multi-omics portfolio.
  • Roche (Ventana Digital Pathology): Roche's Ventana digital pathology business provides slide scanners, image management, and AI-augmented algorithms integrated into a global pathology ecosystem. It is an incumbent serving similar pathologist end users and biopharma partners, with portfolio scale that exceeds 4D Path's offering.
  • Philips Digital Pathology: Philips offers the IntelliSite Digital Pathology platform (iSyntax format, supported by QPOR) along with AI-driven pathology applications. It is comparable as a broad incumbent scanner and workflow vendor reaching the same pathologist and clinical-trial customer base.

Emerging players

  • Strata Oncology: Strata Oncology focuses on molecular profiling and precision oncology decision support, including treatment selection for advanced cancer patients. It overlaps with 4D Path on the precision oncology / companion-diagnostic axis but primarily uses molecular rather than H&E image-based biomarkers.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

4D Path social profiles

Digital presence

4D Path compliance and trust

Trust signal

Compliance5 records

4D Path financial estimates

Financial estimate

Revenue estimate

Valuation estimate

4D Path leadership team

Management profile

Number of profiles

Profiles11 records

4D Path funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

4D Path M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 4D Path

What does 4D Path do?

4D Path develops and sells the Q-Plasia OncoReader (QPOR™) platform, a patented cloud-based AI software that converts digitized H&E-stained whole-slide biopsy and cytology images into predictive biomarkers of cancer therapy response by quantifying cell cycle deregulation and tumor immune microenvironment dynamics. The company sells its breast-cancer-specific 4D QPOR Breast product (FDA Breakthrough Device Designation) and develops customized treatment prediction signatures in partnership with biopharmaceutical companies, clinical research organizations, and academic cancer centers.

Is 4D Path a public or private company?

4D Path is a private company. It is classified as venture growth investor backed and is currently operating.

When was 4D Path founded?

4D Path was founded in 2016. It employs 11 to 50 people.

Where is 4D Path based?

4D Path is headquartered in Newton, United States, in the North America region.

How does 4D Path make money?

Four revenue lines are on record. Biopharma biomarker discovery and development partnerships are the primary driver. The others are clinical trial biomarker analytics, strategic financing rounds (capital raises) and platform distribution via PathPresenter ClinPx.

Who are 4D Path's main competitors?

Direct peers on record are Paige.AI, PathAI, Ibex Medical Analytics, Owkin and Proscia. Broad incumbents are SOPHiA GENETICS, Tempus Labs, Roche (Ventana Digital Pathology) and Philips Digital Pathology. Strata Oncology is listed as an emerging player.

Does 4D Path have an API?

No public API is recorded for 4D Path.

What industry is 4D Path in?

4D Path's product category is Computational Pathology & Predictive Oncology Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 541714 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.04D Path Announces Strategic Financing And Two New Board Appointments4D Path, a Newton, Massachusetts-based cancer care company, has announced the first close of a strategic financing round alongside the appointment of Katherine Vega Stultz as Board Chair and Robert J. Hombach as a director. The financing will accelerate development of treatment predictive biomarkers for clinical use and partnerships with biopharma companies. Stultz brings experience from directing clinical projects at Celgene, while Hombach previously served as EVP, CFO and COO of Baxalta and CFO of Baxter.BioWorldFinancings for May 6, 2026On May 6, 2026, biopharma and med-tech companies including 4D Path, Abivax, Cellectar, Clene, Hemab, Ocugen, Picard Medical, and Senseonics raised funds through public or private financings. No further details on the amounts or terms were disclosed.FinSMEs4D Path Closes Funding4D Path, a Newton, MA-based cancer care company, raised an undisclosed amount in funding. The company will use the funds to accelerate development of treatment predictive biomarkers and pursue biopharma partnerships. It also appointed two new board members.citybiz4D Path Secures Strategic Financing, Expands Board With Oncology and Biopharma Leaders4D Path, a precision oncology company, announced the first close of a strategic financing round alongside the appointment of Katherine Vega Stultz as Board Chair and Robert J. Hombach to its Board of Directors. The capital raise and governance additions are intended to accelerate development of its Q-Plasia OncoReader treatment-predictive biomarker platform and expand partnerships with biopharmaceutical companies. Stultz brings experience from Celgene's global clinical development operations, while Hombach brings healthcare finance and operational leadership from his roles at Baxter International and Baxalta, where he played a key role in its spin-off and acquisition by Shire.Briefglance4D Path Adds Industry Vets, Secures Funds to Scale AI Cancer Platform4D Path announced the first close of a new financing round and appointed two biopharmaceutical veterans—Katherine Vega Stultz as Board Chair and Robert J. Hombach to the Board—to accelerate commercialization of its QPOR™ cancer therapy prediction platform. The company has validated its technology across six cancer types, demonstrating over 80% accuracy in predicting Triple-Negative Breast Cancer patient response to chemotherapy, compared to approximately 40% accuracy for standard care. The new capital and leadership additions support 4D Path's transition from research entity to commercial player, with plans to forge biomarker partnerships with biopharma companies.Business Wire Blog4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors4D Path announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for solid tumors. The company also appointed Katherine Vega Stultz as Board Chair and Robert J. Hombach to its Board of Directors to support this growth phase.BioSpace4D Path Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Predictive Biomarkers for an Antibody Drug Conjugate Program4D Path announced a collaboration with Daiichi Sankyo to develop predictive biomarkers for an antibody drug conjugate program. The partnership will apply 4D Path's Q-Plasia OncoReader platform to routine H&E-stained biopsy slides to compute cell-cycle and microenvironment biomarkers, aiming to improve patient selection and accelerate clinical trials.GlobeNewswire4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer4D Path announced its participation as an exploratory biomarker collaborator in the Phase II DAD-IO clinical study for locally advanced or metastatic urothelial carcinoma (bladder cancer), led by Dana-Farber Cancer Institute and supported by Gilead Sciences. The company will apply its proprietary QPOR platform to analyze pre-treatment biopsy slides and generate predictive biomarkers for response to a novel combination therapy combining two antibody drug conjugates (Sacituzumab Govitecan and Enfortumab Vedotin) with or without the immunotherapy Pembrolizumab. Analysis of pre-treatment biopsies is expected to begin in early 2026, with the trial continuing for approximately 12–18 months.Bloomberg4D Path Inc - Company Profile and News - Bloomberg Markets4D Path Inc., a biotechnology and digital pathology company, offers an AI-powered platform called QPOR for analyzing tissue biopsies for cancer diagnostics and predictive oncology. The company serves customers worldwide.Bio-itworld4D Path Collaborates with AMD and Oracle to Scale Predictive Oncology4D Path announced a collaboration with AMD and Oracle to deploy its QPOR predictive oncology platform on Oracle Cloud Infrastructure using AMD EPYC CPUs. This partnership aims to accelerate clinical trials by providing reproducible, cost-efficient biomarkers from routine biopsy images for personalized cancer care.